Socios

Quibim Accelerates US Expansion with Top Talent and Joins EUCAIM Project to Advance Precision Medicine Access

Quibim, a leading innovator in advanced medical solutions, has recently announced significant milestones in its expansion plans

Quibim-AseBio-Biotecnologia
Corporativo

Quibim, a leading medical imaging solutions provider, has recently announced significant milestones in its expansion plans. The company has successfully onboarded a highly skilled team for its US division and partnered with the European Commission's EUCAIM project to improve cancer detection, diagnosis, and treatment.

The new team members include Dr. Glen Weiss, MD, MBA, as Chief Medical Officer (CMO), Pamod Hemakumara as Corporate Development Director, Parco Chan as Strategy Director, Sarah Vizel as a new project manager, and Ana Centelles as a Business Developer. With his extensive experience in clinical investigation, translational research, and medical oncology, Dr. Weiss will lead Quibim's medical division and provide strategic guidance on personalized medicine, scientific development, and clinical applications. Hemakumara and Chan will spearhead conversations with the Pharma industry to define strategic partnerships, while Vizel will ensure smooth communication between all parties and better serve the medical community. Centelles will identify new business opportunities and support the company's financial strategy to fuel its global growth.

Quibim's expansion in the US market is gaining momentum, and these key hires will play a vital role in supporting its growth plans. The company is excited about its future in the US and is eager to share further updates soon.

In addition to the US expansion, Quibim has joined forces with the European Commission's EUCAIM project to create a secure and accessible pan-cancer hub for medical image data. The project, part of the European Cancer Imaging Initiative, aims to build a digital infrastructure for storing and analyzing cancer images without identifying patient data. Quibim will contribute its QP-Discovery platform as the main backbone for the Central Atlas of Medical Images and provide tools for image de-identification and annotation. The company will also offer image and feature harmonization pipelines to minimize batch effects on datasets used to train models in the EUCAIM infrastructure.

Quibim's participation in the EUCAIM consortium demonstrates its commitment to making precision medicine accessible to a broader range of healthcare organizations. By providing universal access to crucial information, Quibim, and the EUCAIM project strive to improve early cancer detection, diagnosis, and treatment, ultimately benefiting patients worldwide.

With its ongoing US expansion and involvement in the EUCAIM project, Quibim is poised to make a significant impact on the medical imaging industry and contribute to the advancement of precision medicine globally.